Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$2,764 Mln
P/E Ratio
--
P/B Ratio
11.26
Industry P/E
--
Debt to Equity
0.26
ROE
-0.22 %
ROCE
-15.91 %
Div. Yield
0 %
Book Value
9.09
EPS
-1.94
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
GeneDx Holdings
| 19.14 | 19.93 | 15.62 | 662.45 | -3.63 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
|
|---|---|
|
GeneDx Holdings
| 2,620.05 |
|
S&P Small-Cap 600
| 7.01 |
|
BSE Sensex
| 8.10 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 149.47 | 11,476.00 | 13.37 | 159.08 | |
| 97.65 | 9,666.05 | 21.38 | 24.54 | |
| 125.33 | 11,668.49 | 3.75 | 110.75 | |
| 175.31 | 10,659.68 | 9.74 | 17.71 |
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is... headquartered in Stamford, Connecticut. Address: North Tower, Stamford, CT, United States, 06902 Read more
President, CEO & Director
Ms. Katherine A. Stueland
President, CEO & Director
Ms. Katherine A. Stueland
Headquarters
Stamford, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GeneDx Holdings Corp stood at $ 419 Mln as on 31-Dec-24
The share price of GeneDx Holdings Corp is $91.57 (NASDAQ) as of 18-Mar-2025 14:35 EDT. GeneDx Holdings Corp has given a return of -3.63% in the last 3 years.
GeneDx Holdings Corp has a market capitalisation of $ 2,764 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of GeneDx Holdings Corp is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GeneDx Holdings Corp and enter the required number of quantities and click on buy to purchase the shares of GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is headquartered in Stamford, Connecticut. Address: North Tower, Stamford, CT, United States, 06902
The CEO & director of Ms. Katherine A. Stueland. is GeneDx Holdings Corp, and CFO & Sr. VP is Ms. Katherine A. Stueland.
There is no promoter pledging in GeneDx Holdings Corp.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,199
|
|
|
1,155
|
|
|
1,133
|
|
|
1,007
|
| GeneDx Holdings Corp | Ratios |
|---|---|
|
Return on equity(%)
|
-22.1
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-17.12
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GeneDx Holdings Corp was $-52 Mln.
$-2.89
(
